Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals PLC (HKMPY)
OTHER OTC:HKMPY
Earnings Data
Report Date
Feb 19, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
―Last Year’s EPS
1.19Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed performance for Hikma in the first half of 2025. While there was notable revenue growth and strategic advancements, challenges such as declining core operating profit and increased costs impacted overall performance. However, the company maintains a positive outlook for the second half, supported by strategic investments and robust balance sheet management.Company Guidance
Strong Revenue Growth
Hikma delivered a 6% revenue growth driven by robust volumes across all business segments and regions, with recent launches and the Xellia acquisition contributing to growth.
Injectables Segment Performance
Injectables segment showed consistent strong momentum with a 12% core revenue growth year-on-year, supported by the Xellia acquisition and strong demand in Europe and MENA.
Strategic Partnerships and Pipeline Expansion
Hikma signed new strategic partnerships and enhanced manufacturing capabilities, significantly expanding its pipeline and positioning for future growth.
Strong Performance in Europe and MENA
European revenue grew by 26% and MENA by 16% in the Injectables segment, driven by expanding portfolios and market shortages.
Branded Segment Growth
The Branded segment delivered 4% top-line growth and 3% operating profit growth, maintaining a strong position as the second largest pharmaceutical company in MENA.
Robust Balance Sheet
Hikma maintained a robust balance sheet with a leverage ratio below 2x at 1.7x net debt to core EBITDA, despite higher debt utilization for acquisitions.
HKMPY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HKMPY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | $49.50 | $46.24 | -6.59% |
Feb 26, 2025 | $56.24 | $52.94 | -5.87% |
Aug 08, 2024 | $44.79 | $48.46 | +8.19% |
Feb 22, 2024 | $47.31 | $49.37 | +4.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Hikma Pharmaceuticals PLC (HKMPY) report earnings?
Hikma Pharmaceuticals PLC (HKMPY) is schdueled to report earning on Feb 19, 2026, TBA (Confirmed).
What is Hikma Pharmaceuticals PLC (HKMPY) earnings time?
Hikma Pharmaceuticals PLC (HKMPY) earnings time is at Feb 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HKMPY EPS forecast?
Currently, no data Available